hereditary angioedema

遗传性血管性水肿
  • 文章类型: Case Reports
    遗传性血管性水肿(HAE)是一种以C1-INH基因突变为特征的罕见常染色体显性疾病,导致影响身体各个部位的复发性血管性水肿发作,包括胃肠道.该病例报告描述了一名24岁的女性,表现出模仿急腹症的症状,以严重的腹部绞痛为特征,厌食症,腹泻,在11岁时有明显的血管性水肿耀斑和紧急插管窒息病史。尽管最初用抗组胺药治疗没有改善,她的症状自发缓解。进一步调查显示补体C4水平低,C1-INH功能降低,确认HAE与升结肠和横结肠的异常分离受累。该病例强调了在出现急性腹部症状的患者中考虑HAE的重要性,尤其是有血管性水肿病史.它强调急诊医师和胃肠病学家需要了解HAE的临床表现,以避免误诊和不必要的干预。此外,该案例强调了患者教育对识别症状和及时就医以预防严重并发症的重要性。本报告通过详细介绍HAE的罕见表现来增加现有文献,旨在加强对这种潜在危及生命的疾病的早期诊断和管理。
    Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by C1-INH gene mutations, leading to recurrent angioedema episodes affecting various body parts, including the gastrointestinal tract. This case report describes a 24-year-old female presenting with symptoms mimicking an acute abdomen, characterized by severe abdominal cramps, anorexia, and diarrhea, with a significant past medical history of angioedema flares and emergency intubation for asphyxiation at age 11. Despite initial treatment with antihistamines showing no improvement, her symptoms spontaneously resolved. Further investigation revealed low complement C4 levels and reduced C1-INH function, confirming HAE with an unusual isolated involvement of the ascending and transverse colon. This case underscores the importance of considering HAE in patients presenting with acute abdominal symptoms, especially with a history suggestive of angioedema. It highlights the need for emergency physicians and gastroenterologists to be aware of HAE\'s clinical manifestations to avoid misdiagnosis and unnecessary interventions. Moreover, the case emphasizes the significance of patient education on recognizing symptoms and seeking timely medical attention to prevent severe complications. This report adds to the existing literature by detailing an uncommon presentation of HAE, aiming to enhance early diagnosis and management of this potentially life-threatening condition.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    心理治疗在慢性病管理中的作用已得到广泛的探索和支持。目前在治疗计划中使用面向家庭的心理治疗的方法是针对患者个性化,并侧重于个人应对技巧的发展,同时识别和改变负面想法,情感,和行为。减轻症状负担,改善精神病并存的疾病,如焦虑和抑郁,和生活质量的提高都被发现与在慢性病的管理中纳入面向家庭的心理治疗有关。相比之下,可遗传的条件,如遗传性血管性水肿(HAE),并不是广泛研究的中心。遗传条件引入了一种新的压力源,需要管理,例如父母的焦虑,一个兄弟姐妹,一个孩子,或与自己同时失代偿的另一个家庭成员。以家庭为中心的心理治疗侧重于讨论家庭单位的压力源和应对策略的发展,以防止一个家庭成员的病情的时间过程加剧另一个家庭成员的病情。该模型已用于患有不同慢性病的家庭,但是它在管理遗传条件方面的作用和有效性还有研究的余地。本文介绍了一个家庭参与以家庭为中心的HAE心理治疗的案例系列。
    The role of psychotherapy in the management of chronic conditions has been widely explored and supported. The current approach to the utilization of family-oriented psychotherapy in treatment plans is individualized to the patient and focused on the development of personal coping skills alongside identifying and changing negative thoughts, emotions, and behaviors. Alleviation of symptom burden, improvement in psychiatric co-morbidities like anxiety and depression, and enhancement of quality of life have all been found to be associated with incorporating family-oriented psychotherapy in the management of chronic conditions. In contrast, heritable conditions, such as hereditary angioedema (HAE), have not been the center of extensive research. Heritable conditions introduce a new category of stressors that require management like the anxiety of a parent, a sibling, a child, or another family member decompensating at the same time as oneself. Family-centered psychotherapy focuses on discussing the stressors of the family unit and the development of coping strategies to prevent the time course of one family member\'s condition from exacerbating another family member\'s condition. This model has been utilized for families with separate chronic conditions, but its role and effectiveness in managing inherited conditions have room for investigation. This paper presents a case series on a family engaging in family-centered psychotherapy for HAE.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:由于C1抑制剂缺乏症(C1INH)引起的遗传性血管性水肿(HAE)是一种罕见的疾病,临床特征为复发性肿胀。攻击的不可预测性影响患者的生活质量(QoL)。HAE患者及其家人有大量未满足的身体,心理,和社会需求。以人为中心的设计(HCD)方法来描述不同用户类型的需求是利用角色,一种数据驱动的叙事工具,用于传达捕捉个人态度的用户原型,目标,和行为。这项研究的目的是根据HAE患者及其护理人员的访谈创建和分析角色。半结构化访谈是通过与患者的人类学对话进行的,患者-护理人员(患者和护理人员的双重角色),和未受影响的护理人员。来自分析的定性和定量见解构成了创建角色的基础。
    结果:我们招募了17名受试者:15名患者(其中6名是患者照顾者)和2名未受影响的照顾者。参与者的平均年龄为50.3±14.4岁。8例患者接受预防性治疗。HAE患者的血管性水肿生活质量(AE-QoL)的平均百分比评分为19.8±12.0。确定了六个描述参与者个人历史的角色,疾病管理,和需求:四个角色指的是病人,一个给病人护理人员,并确定了一名未受影响的护理人员。跨患者角色,表达最多的需求是医疗专业人员的心理支持和更好的意识。看护者,在他们这边,想要更好的疾病信息,包括最新的疗法,以及社区内更高的意识。
    结论:基于人物角色的以人为本的创新方法超出了身体症状,涵盖了个人福祉的心理和社会方面,也包括评估中的家庭。
    BACKGROUND: Hereditary Angioedema (HAE) due to C1-inhibitor deficiency (C1INH) is a rare condition, clinically characterised by recurrent swelling. The unpredictability of attacks affects the patients\' quality of life (QoL). HAE patients and their families have vast unmet physical, psychological, and social needs. A human-centred design (HCD) approach to describing the needs of different user types is to utilise personas, a data-driven narrative tool for communicating user archetypes that capture the individuals\' attitudes, goals, and behaviours. The aim of this study was to create and analyse personas based on HAE patients\' and their caregivers\' interviews. Semi-structured interviews were conducted through anthropological conversations with patients, patient-caregivers (double role of patient and caregiver), and non-affected caregivers. Qualitative and quantitative insights from analyses formed the basis to create personas.
    RESULTS: We enrolled 17 subjects: 15 patients (6 of them were patient-caregivers) and 2 non-affected caregivers. The mean age of participants was 50.3 ± 14.4 years. Eight patients were on treatment with prophylactic therapy. The mean percentage score of Angioedema Quality of Life (AE-QoL) for HAE patients was 19.8 ± 12.0. Six personas were identified describing the participants\' personal history, disease management, and needs: four personas referred to patients, one to patient-caregivers, and one non-affected caregiver personas were identified. Across patient personas, the most expressed needs were psychological support and better awareness amongst healthcare professionals. Caregivers, on their side, desired better information about the disease, including the latest therapies, and higher awareness within the community.
    CONCLUSIONS: A Human Centred Innovative Approach Based on Persona extends beyond the physical symptoms to encompass the psychological and social aspects of the individual\'s well-being also including the family in the evaluation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    复发性血管性水肿的影响可能会严重衰弱,并且仍然难以量化。几种标准化的患者报告结果测量(PROM),包括血管水肿活动评分(AAS),血管性水肿生活质量(AE-QoL)问卷,和血管性水肿控制测试(AECT),已经被开发并翻译成不同的语言。然而,这些PROM尚未在中国个人中得到验证,它们在中国人口中的相关性仍然未知。
    我们的目的是验证AAS的中文版本,AE-QoL问卷,和AECT,并评估它们的相互关系。
    在香港血管水肿和荨麻疹参考和卓越中心进行的118例复发性血管性水肿的中国患者的前瞻性队列研究完成了AAS的繁体中文版本,AE-QoL问卷,和AECT。我们分析了这些PROM的信度和效度及其相互之间以及与通用PROM的相关性。
    中国AAS,AE-QoL问卷,和AECT表现出优异的内部一致性(Cronbachα分别为0.920、0.976和0.832;McDonaldω分别为0.972、0.977和0.901)。AE-QoL问卷的验证性因素分析显示与4维模型的拟合可接受(比较拟合指数=0.869;Tucker-Lewis指数=0.842)。AECT与AAS和AE-QoL问卷均具有显着相关性(ρ分别为-0.750和-0.456[均P<0.05])。AE-QoL问卷与通用PROM的某些领域中度相关,例如工作生产力和活动损害问卷:一般健康,2.0版和简短表格12项健康调查,版本2(所有ρ<0.60)。
    中国AE-QoL问卷,AAS,和AECT是中国患者使用的有效和可靠的工具。应提供更多经过验证的工具,以改善全球所有血管性水肿患者的患者护理和研究。
    UNASSIGNED: The impact of recurrent angioedema can be severely debilitating and remains difficult to quantify. Several standardized patient-reported outcome measures (PROMs), including the Angioedema Activity Score (AAS), Angioedema Quality of Life (AE-QoL) questionnaire, and Angioedema Control Test (AECT), have been developed and translated into different languages. However, these PROMs have yet to be validated in Chinese individuals, and their correlations in the Chinese population remain unknown.
    UNASSIGNED: Our aim was to validate the Chinese versions of the AAS, AE-QoL questionnaire, and AECT and assess their intercorrelations.
    UNASSIGNED: A prospective cohort of 118 Chinese patients with recurrent angioedema at the Angioedema and Urticaria Centre of Reference and Excellence in Hong Kong completed the traditional Chinese versions of the AAS, AE-QoL questionnaire, and AECT. We analyzed the reliability and validity of these PROMs and their correlations with each other as well as with generic PROMs.
    UNASSIGNED: The Chinese AAS, AE-QoL questionnaire, and AECT demonstrated excellent internal consistency (Cronbach α = 0.920, 0.976, and 0.832, respectively; McDonald ω = 0.972, 0.977, and 0.901, respectively). Confirmatory factor analysis for the AE-QoL questionnaire showed an acceptable fit with the 4-dimensional model (comparative fit index = 0.869; Tucker-Lewis index = 0.842). The AECT showed significant correlations with both the AAS and AE-QoL questionnaire (ρ = -0.750 and -0.456 respectively [both P < .05]). The AE-QoL questionnaire was moderately correlated with certain domains of generic PROMs such as the Work Productivity and Activity Impairment Questionnaire: General Health, version 2.0, and the Short Form 12-Item Health Survey, version 2 (all ρ < 0.60).
    UNASSIGNED: The Chinese AE-QoL questionnaire, AAS, and AECT are valid and reliable tools for use with Chinese patients. More validated tools should be made available to improve patient care and research for all patients with angioedema globally.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    由于C1抑制剂缺乏症(HAE)引起的遗传性血管性水肿是一种罕见的先天性免疫错误,表现为偶发性肿胀。管理是多方面的,包括按需治疗肿胀发作,短期预防以防止手术引起的肿胀发作,和长期预防(LTP)以持续预防血管性水肿。所有批准的按需治疗都是肠胃外治疗,需要对病人进行家庭管理培训,特别是静脉内C1抑制剂。这些复杂性可能导致农村HAE患者的护理差距。我们在我们的血管性水肿参考和卓越中心进行了一项横断面研究,以评估为城市和农村患者提供的护理。接受LTP的患者比例,被诊断为儿童的患者比例,收集使用血管性水肿控制测试(AECT)测量的疾病控制。采用经年龄和性别调整的Logistic和泊松回归模型比较两组。城乡患者使用LTP的比例相似,分别为62%和61%,分别(比值比[OR]1.01(CI95%0.34-2.99))。在城市患者中,52%被诊断为儿童,而农村居民为60%(1.43(0.37-5.56))。城市患者的平均(IQR)AECT评分为14.0(8.5-15.5),农村患者为13.0(10.0-14.0)(泊松β-0.001(-0.23-0.23)。这些数据表明,农村患者接受了类似的高质量护理。我们将这些发现归因于所采用的集中护理模式,该模式在单个综合护理诊所中看到该地区的HAE患者。
    Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a rare inborn error of immunity that presents with episodic swelling. Management is multifaceted and includes on-demand treatment of swelling episodes, short-term prophylaxis to prevent swelling episodes from procedures, and long-term prophylaxis (LTP) to prevent angioedema on an ongoing basis. All approved on-demand therapies are parenteral, necessitating patient training for home administration, particularly intravenous C1 inhibitor. These complexities can result in care gaps for rural HAE patients. We conducted a cross-sectional study at our Angioedema Center of Reference and Excellence to assess the care provided to urban and rural patients. The proportion of patients receiving LTP, proportion of patients diagnosed as children, and disease control measured using the Angioedema Control Test (AECT) were collected. Logistic and Poisson regression models adjusted for age and sex were used to compare the two groups. The proportion using LTP was similar at 62% and 61% in urban and rural patients, respectively (odds ratio [OR] 1.01 (CI 95% 0.34-2.99)). Among urban patients, 52% were diagnosed as children compared to 60% among rural residents (1.43 (0.37-5.56)). The mean (IQR) AECT score was 14.0 (8.5-15.5) in urban patients and 13.0 (10.0-14.0) in rural patients (Poisson β -0.001 (-0.23-0.23). These data indicate that rural patients received similar high-quality care. We attribute these findings to the centralized care model employed in which HAE patients in the region are seen at a single comprehensive care clinic.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    遗传性血管性水肿(HAE)是一种罕见的遗传性疾病,其特征是由C1抑制剂(C1-INH)缺乏或功能障碍引起的局部水肿反复发作。此病例报告介绍了临床特征,诊断评估,以及一名23岁的HAE患者的管理。我们讨论了诊断和治疗这种疾病的挑战,强调早期识别和适当治疗干预的重要性。
    Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of localized edema caused by a deficiency or dysfunction of C1 inhibitor (C1-INH). This case report presents the clinical features, diagnostic evaluation, and management of a 23-year-old man with HAE. We discuss the challenges of diagnosing and treating this condition, emphasizing the importance of early recognition and appropriate therapeutic interventions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    激活的FXII(FXIIa)是血浆接触系统的主要引发剂,并且可以激活促凝血和促炎途径。其活性在遗传性血管性水肿(HAE)的病理生理学中很重要。这里,我们描述了与garadacimab的Fab片段复合的FXIIa(βFXIIa)的β链的高分辨率低温电子显微镜(cryo-EM)结构。Garadacimab通过异常长的CDR-H3与βFXIIa结合,该CDR-H3以非规范方式插入S1口袋。这种结构机制可能是抑制HAE中活化的FXIIa蛋白水解活性的主要贡献者。GaradacimabFab-βFXIIa结构还揭示了garadacimab与活化的FXIIa的高亲和力结合的关键决定因素。用其他真正的FXIIa抑制剂进行结构分析,如苄脒和C1-INH,揭示了garadacimab抑制βFXIIa的惊人相似机制。总之,garadacimabFab-βFXIIa结构提供了对其作用机制的重要见解,并描述了主要和辅助互补位/表位。
    Activated FXII (FXIIa) is the principal initiator of the plasma contact system and can activate both procoagulant and proinflammatory pathways. Its activity is important in the pathophysiology of hereditary angioedema (HAE). Here, we describe a high-resolution cryoelectron microscopy (cryo-EM) structure of the beta-chain from FXIIa (βFXIIa) complexed with the Fab fragment of garadacimab. Garadacimab binds to βFXIIa through an unusually long CDR-H3 that inserts into the S1 pocket in a non-canonical way. This structural mechanism is likely the primary contributor to the inhibition of activated FXIIa proteolytic activity in HAE. Garadacimab Fab-βFXIIa structure also reveals critical determinants of high-affinity binding of garadacimab to activated FXIIa. Structural analysis with other bona fide FXIIa inhibitors, such as benzamidine and C1-INH, reveals a surprisingly similar mechanism of βFXIIa inhibition by garadacimab. In summary, the garadacimab Fab-βFXIIa structure provides crucial insights into its mechanism of action and delineates primary and auxiliary paratopes/epitopes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:遗传性血管性水肿(HAE)是一种罕见且可能危及生命的疾病,在临床上表现为反复发作的肿胀影响多个解剖部位。长期预防(LTP)旨在通过预防HAE发作来控制疾病。以前,减毒雄激素等治疗已用于LTP,但是它们有不利的不利影响。今天,这些限制可以通过患者过渡到较新的,靶向治疗包括口服berotralstat和皮下lanadelumab。本病例系列报告了在现实世界中患有HAE的家庭中不同预防疗法之间的过渡过程。
    结果:介绍了来自同一家庭的4例经历了HAE预防过渡的成年患者病例。三个是女性,一个是男性。两名过渡到berotralstat的患者最初服用了减毒雄激素。两名患者在开始靶向治疗时没有服用LTP,但之前已经服用了氨甲环酸。患者之间的过渡长度不同,新疗法稳定所需的最长时间为26个月。所有患者都亲自或通过电话接受了定期随访,所有四名患者都需要对其初始治疗计划进行调整。
    结论:HAE中LTP之间的转换可能有助于改善对发作的控制,避免不必要的不良影响,或更好地满足个人患者的喜好。较新的靶向治疗已被证明是有效的,应与患者讨论。共享决策是可以帮助这些讨论的工具。HAE中LTP疗法之间的过渡过程可能并不简单,并且对每个患者都是特定的。医生应该考虑复杂的因素,如患者对改变治疗的焦虑,不利影响,首选的给药途径,过渡的速度。在过渡期密切关注患者有助于识别任何问题,包括治疗依从性困难,并可能允许在必要时调整过渡计划。
    BACKGROUND: Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that manifests clinically as recurrent episodes of swelling affecting multiple anatomical locations. Long-term prophylaxis (LTP) aims to control the disease by preventing HAE attacks. Previously, treatments such as attenuated androgens have been used for LTP, but they have an unfavorable adverse effect profile. Today, these limitations may be overcome by patients transitioning to newer, targeted therapies including oral berotralstat and subcutaneous lanadelumab. This case series reports the transition process between different prophylactic therapies in a family with HAE in a real-world setting.
    RESULTS: Four adult patient cases from the same family who underwent transitions in HAE prophylaxis are presented. Three were female and one male. Two patients who transitioned to berotralstat were initially prescribed attenuated androgens. Two patients were not taking LTP at the time of initiating targeted treatment but had previously been prescribed tranexamic acid. The length of transition varied between the patients, with the longest time taken to stabilize on new therapy being 26 months. All patients received regular follow-up in person or by telephone and all four required an adjustment from their initial treatment plan.
    CONCLUSIONS: Transitioning between LTP in HAE may help improve control of attacks, avoid unwanted adverse effects, or better cater to individual patient preferences. Newer targeted therapies have been shown to be effective and should be discussed with patients. Shared decision-making is a tool that can aid these discussions. The transition journey between LTP therapies in HAE may not be straightforward and is specific to each patient. Physicians should consider complicating factors such as patient anxieties around changing treatment, adverse effects, preferred routes of administration, and speed of transition. Following patients closely during the transition period helps identify any issues, including difficulties with treatment adherence, and may allow the transition plan to be adapted when necessary.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号